EUCTR2020-003136-25-DE进行中（未招募）1 期
A Phase 3, Double blind, Randomized, Placebo controlled, Parallel group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl ß cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann Pick Disease Type C1
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients =3 years of age at Screening.
- •2. Diagnosis of NPC1 confirmed by:
- •a. Genetically confirmed (deoxyribonucleic acid sequence analysis) by
- •mutations in both alleles of NPC1 OR
- •b. Mutation in only 1 allele of NPC1 and either positive filipin staining in skin or vertical supranuclear gaze palsy (VSGP).
- •3. Patients with an ASIS between 0.5 to 2.0 (inclusive) at Screening
- •using the 17 Domain Niemann-Pick Type C Severity Scale (17D-NPC-SS) composite score. For patients who remain incontinent due to inability to train to become continent, the relative contribution to the 17-D-NPC-CSS composite score can be adjusted per the Investigator's judgment as not applicable, following conferring with the Medical Monitor. A not applicable score will be scored as a 0 for this domain.
- •4.Treated or not treated with miglustat.
- •a. If a patient is receiving treatment with miglustat, the dose must have been stable for at least 3 continuous months prior to the first Screening Visit.
- •b. If a patient has been discontinued from prescribed treatment with
- •miglustat, she/he must have been discontinued for at least 3 continuous months prior to the first Screening Visit.
- •5. Body weight >4.5 kg to =125 kg
- •6. Presenting at least 1 neurological symptom of the disease (including, but not limited to, hearing loss, VSGP, ataxia, dementia, dystonia, history of seizures, cataplexy, dysarthria, or dysphagia)
- •7. Willing and capable to participate in all aspects of study design, including blood sampling (efficacy, PK, blood biomarkers, and safety laboratory tests). Adequate compliance with the assessments to obtain complete data can become a discussion between the Investigator and the medical monitor prior to randomization at the Baseline Visit
- •the Medical Monitor prior to randomization at the Baseline Visit.
- •8.Patients who have previously been treated with hydroxypropyl-ß-
- •cyclodextrin (HPßCD) are eligible for participation in the study if their
- •last intrathecal administration was 3 months or longer ago or if their last IV administration was 6 months or longer ago. No more than
- •approximately 10% of the total number of randomized patients can
- •previously have been exposed to HPßCD.
- •9. Ability to travel to the corresponding clinical study site at the scheduled visit times for evaluation and follow-up
- •10. Contraception requirements:
- •a. All sexually active WOCBP (post menarche) must use highly effective contraception during the study and until 3 months after the last dose of study treatment
- •b. Highly effective birth control methods include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal); progestogen only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable); intrauterine device; intrauterine hormone-releasing system; bilateral tubal occlusion; or vasectomized partner
- •c. All sexually active male patients with WOCBP partners (post menarche) must use a condom with or without spermicide in addition to the birth control used by their partners during the study and until 3 months after the last dose of study treatment
- •d. Sexual abstinence is considered a highly effective birth control method only if it is defined as refraining from heterosexual intercourse during the study and for 3 months after the last dose of study treatment for WOCBP and for male patients with WOCBP partners. The reliability of sexual abstinence needs to be evaluat
排除标准
- •1. Recipient of a liver transplant within <12 months or planned liver transplantation. Patients who have received a successful transplant
- •over 12 months or longer ago can be screened.
- •2. Patients with active liver disease from any cause other than NPC1 or prolonged icterus or malformation of organs other than NPC1
- •3. Clinical evidence of acute liver disease including associated symptoms of jaundice or right upper quadrant pain or international normalized ratio >1.8
- •4. Stage 3 chronic kidney disease or worse as indicated by an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. In patients aged =18 years, eGFR is calculated according to the Schwartz equation (Schwartz and Work, 2009), and in patients aged >18 years eGFR is calculated using the Modification of Diet in Renal Disease equation
- •5. Use of curcumin or fish oil supplements within 12 weeks prior to enrollment
- •6. Known or suspected allergy or intolerance to the study treatment
- •7. Treatment with any investigational drug during the 3 months prior to entering the study. If the investigational drug has a short half-life (<8 hours) and would be expected to be cleared from the body within 1 month, then the wash-out period is 1 month. Treatment with any form of leucine, whether as an investigational drug or other formulation is not allowed. Please consult with the Medical Monitor on a case-by-case basis.
- •8. Treatment with any other investigational drug during the study
- •9. Pregnancy or breastfeeding
- •10. Current participation in another study is not permitted unless it is a noninterventional study and the sole purpose of the trial is for long term follow up describing clinical features or survival data (registry)
- •11. Patients with uncontrolled, severe epileptic seizure periods (at least 3 consecutive severe epileptic seizures that required medication) within 2 months prior to completion of informed consent (or assent, as applicable). This includes patients with ongoing seizures that are not stable in frequency or type or duration over a 2-month period prior to enrollment, requiring change in dose of antiepileptic medication (other than adjustment for weight) over a 2-month period prior to enrollment, or requiring 3 or more antiepileptic medications to control seizures over a 2-month period prior to enrollment
- •12. Neurologically asymptomatic patients
- •13. Inability to participate in the primary study assessment (4D-NPC-SS and 5D-NPC-SS) as determined by the Investigator.
研究者
相似试验
进行中（未招募）
1 期
Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann Pick Disease Type C1EUCTR2020-003136-25-FRCyclo Therapeutics, Inc.105
进行中（未招募）
1 期
Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann Pick Disease Type C1iemann Pick Disease Type C1MedDRA version: 20.0Level: PTClassification code 10029403Term: Niemann-Pick diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-003136-25-ESCyclo Therapeutics, Inc.105
招募中
3 期
Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann Pick Disease Type C12024-518266-27-00Cyclo Therapeutics Inc.36
进行中（未招募）
1 期
Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann Pick Disease Type C1iemann Pick Disease Type C1MedDRA version: 20.0Level: PTClassification code 10029403Term: Niemann-Pick diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-003136-25-PLCyclo Therapeutics, Inc.105
招募中
3 期
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell LymphomaMantle Cell Lymphoma2023-509354-58-00Acerta Pharma B.V.198